GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06
Executive Summary
GlaxoSmithKline's strategy of building its oncology business is paying off with a range of new chemical entities entering Phase III development within the next year for cancer-related indications, executives said during an oncology R&D update in New York
You may also be interested in...
Tykerb Effective In Herceptin Failures; CNS Relapse Rate, CV Safety Touted
GlaxoSmithKline's Tykerb (lapatinib) should replace Genentech's Herceptin (trastuzumab) as the standard of care for trastuzumab-refractory breast cancer patients, GSK Senior VP-Oncology Medicine Development Center Paolo Paoletti said June 3
Tykerb Effective In Herceptin Failures; CNS Relapse Rate, CV Safety Touted
GlaxoSmithKline's Tykerb (lapatinib) should replace Genentech's Herceptin (trastuzumab) as the standard of care for trastuzumab-refractory breast cancer patients, GSK Senior VP-Oncology Medicine Development Center Paolo Paoletti said June 3
Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers
Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment